CA Patent

CA3013321A1 — Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties

Assigned to Specgx LLC · Expires 2017-08-17 · 9y expired

What this patent protects

A pharmaceutical composition comprising at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, a glucomannan, a first polyalkylene oxide having an average molecular weight of no more than 300,000, and a second polyalkylene oxide having …

USPTO Abstract

A pharmaceutical composition comprising at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, a glucomannan, a first polyalkylene oxide having an average molecular weight of no more than 300,000, and a second polyalkylene oxide having an average molecular weight of at least 1,000,000 and methods of making. The pharmaceutical composition extended release of the API and has abuse deterrent features.

Drugs covered by this patent

Patent Metadata

Patent number
CA3013321A1
Jurisdiction
CA
Classification
—
Expires
2017-08-17
Drug substance claim
No
Drug product claim
No
Assignee
Specgx LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.